1 2 dipalmitoyl sn glycero 3 phosphocholine (Croda International Plc)
99
Structured Review
Croda International Plc
1 2 dipalmitoyl sn glycero 3 phosphocholine
1 2 Dipalmitoyl Sn Glycero 3 Phosphocholine, supplied by Croda International Plc, used in various techniques. Bioz Stars score: 99/100, based on 2887 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pc/16%3A0+PC/pmc13059125-101-1-3
Average 99 stars, based on 2887 article reviews
1 2 Dipalmitoyl Sn Glycero 3 Phosphocholine, supplied by Croda International Plc, used in various techniques. Bioz Stars score: 99/100, based on 2887 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pc/16%3A0+PC/pmc13059125-101-1-3
Average 99 stars, based on 2887 article reviews
1 2 dipalmitoyl sn glycero 3 phosphocholine - by Bioz Stars,
2026-11
99/100 stars
Images
Related Articles
Liposomes:Article Title: Developing a pan cancer therapy based on DISE-inducing short RNAs Article Snippet: To transform cells, they were infected in basal medium with the retroviral supernatant produced using the vectors pBABE-puro SV40 LT (Addgene, Cat #1370) or pBABE hygro hTERT (Addgene, Cat #1773) in Phoenix-Ampho cells (Orbigen, Cat# RVK-10001 or ATCC, CRL-3213), following standard retroviral procedures. Preserving:Article Title: Developing a pan cancer therapy based on DISE-inducing short RNAs Article Snippet: To transform cells, they were infected in basal medium with the retroviral supernatant produced using the vectors pBABE-puro SV40 LT (Addgene, Cat #1370) or pBABE hygro hTERT (Addgene, Cat #1773) in Phoenix-Ampho cells (Orbigen, Cat# RVK-10001 or ATCC, CRL-3213), following standard retroviral procedures. High Performance Liquid Chromatography:Article Title: Developing a pan cancer therapy based on DISE-inducing short RNAs Article Snippet: To transform cells, they were infected in basal medium with the retroviral supernatant produced using the vectors pBABE-puro SV40 LT (Addgene, Cat #1370) or pBABE hygro hTERT (Addgene, Cat #1773) in Phoenix-Ampho cells (Orbigen, Cat# RVK-10001 or ATCC, CRL-3213), following standard retroviral procedures. Generated:Article Title: Developing a pan cancer therapy based on DISE-inducing short RNAs Article Snippet: To transform cells, they were infected in basal medium with the retroviral supernatant produced using the vectors pBABE-puro SV40 LT (Addgene, Cat #1370) or pBABE hygro hTERT (Addgene, Cat #1773) in Phoenix-Ampho cells (Orbigen, Cat# RVK-10001 or ATCC, CRL-3213), following standard retroviral procedures. Microscale Thermophoresis:Article Title: Developing a pan cancer therapy based on DISE-inducing short RNAs Article Snippet: To transform cells, they were infected in basal medium with the retroviral supernatant produced using the vectors pBABE-puro SV40 LT (Addgene, Cat #1370) or pBABE hygro hTERT (Addgene, Cat #1773) in Phoenix-Ampho cells (Orbigen, Cat# RVK-10001 or ATCC, CRL-3213), following standard retroviral procedures. Affinity Binding Assay:Article Title: Developing a pan cancer therapy based on DISE-inducing short RNAs Article Snippet: To transform cells, they were infected in basal medium with the retroviral supernatant produced using the vectors pBABE-puro SV40 LT (Addgene, Cat #1370) or pBABE hygro hTERT (Addgene, Cat #1773) in Phoenix-Ampho cells (Orbigen, Cat# RVK-10001 or ATCC, CRL-3213), following standard retroviral procedures. Purification:Article Title: Developing a pan cancer therapy based on DISE-inducing short RNAs Article Snippet: To transform cells, they were infected in basal medium with the retroviral supernatant produced using the vectors pBABE-puro SV40 LT (Addgene, Cat #1370) or pBABE hygro hTERT (Addgene, Cat #1773) in Phoenix-Ampho cells (Orbigen, Cat# RVK-10001 or ATCC, CRL-3213), following standard retroviral procedures. Labeling:Article Title: Developing a pan cancer therapy based on DISE-inducing short RNAs Article Snippet: To transform cells, they were infected in basal medium with the retroviral supernatant produced using the vectors pBABE-puro SV40 LT (Addgene, Cat #1370) or pBABE hygro hTERT (Addgene, Cat #1773) in Phoenix-Ampho cells (Orbigen, Cat# RVK-10001 or ATCC, CRL-3213), following standard retroviral procedures. Suspension:Article Title: Developing a pan cancer therapy based on DISE-inducing short RNAs Article Snippet: To transform cells, they were infected in basal medium with the retroviral supernatant produced using the vectors pBABE-puro SV40 LT (Addgene, Cat #1370) or pBABE hygro hTERT (Addgene, Cat #1773) in Phoenix-Ampho cells (Orbigen, Cat# RVK-10001 or ATCC, CRL-3213), following standard retroviral procedures. Synthesized:Article Title: Developing a pan cancer therapy based on DISE-inducing short RNAs Article Snippet: To transform cells, they were infected in basal medium with the retroviral supernatant produced using the vectors pBABE-puro SV40 LT (Addgene, Cat #1370) or pBABE hygro hTERT (Addgene, Cat #1773) in Phoenix-Ampho cells (Orbigen, Cat# RVK-10001 or ATCC, CRL-3213), following standard retroviral procedures. Binding Assay:Article Title: Developing a pan cancer therapy based on DISE-inducing short RNAs Article Snippet: To transform cells, they were infected in basal medium with the retroviral supernatant produced using the vectors pBABE-puro SV40 LT (Addgene, Cat #1370) or pBABE hygro hTERT (Addgene, Cat #1773) in Phoenix-Ampho cells (Orbigen, Cat# RVK-10001 or ATCC, CRL-3213), following standard retroviral procedures. |